Thermo Fisher Scientific Inc. $TMO Shares Acquired by Qtron Investments LLC

Key Points

• Qtron Investments LLC increased its stake in Thermo Fisher Scientific Inc. by 16.2% in Q1, acquiring an additional 729 shares, bringing its total to 5,242 shares valued at approximately $2.6 million.
• Analysts have given mixed ratings for TMO, with upgrades and downgrades adjusting the target price; the stock has a consensus target price of $593.00 and is rated as a "Moderate Buy."
• Insiders have recently sold shares, with notable transactions from EVP Gianluca Pettiti and CEO Marc N. Casper, indicating a 7.99% decrease in the CEO's ownership following a sale of 10,000 shares.

Qtron Investments LLC grew its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 16.2% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 5,242 shares of the medical research company's stock after acquiring an additional 729 shares during the quarter. Qtron Investments LLC's holdings in Thermo Fisher Scientific were worth $2,608,000 as of its most recent SEC filing.

Several other hedge funds have also recently modified their holdings of the stock. Vanguard Group Inc. boosted its position in Thermo Fisher Scientific by 0.7% in the 1st quarter. Vanguard Group Inc. now owns 33,479,957 shares of the medical research company's stock worth $16,659,627,000 after purchasing an additional 230,382 shares in the last quarter. Northern Trust Corp lifted its holdings in Thermo Fisher Scientific by 13.2% in the 4th quarter. Northern Trust Corp now owns 3,910,015 shares of the medical research company's stock valued at $2,034,107,000 after purchasing an additional 455,004 shares in the last quarter. T. Rowe Price Investment Management Inc. boosted its position in shares of Thermo Fisher Scientific by 86.9% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 3,083,900 shares of the medical research company's stock valued at $1,604,338,000 after acquiring an additional 1,433,444 shares during the last quarter. Charles Schwab Investment Management Inc. increased its position in Thermo Fisher Scientific by 4.1% during the first quarter. Charles Schwab Investment Management Inc. now owns 2,925,591 shares of the medical research company's stock worth $1,455,774,000 after purchasing an additional 115,463 shares during the last quarter. Finally, Pictet Asset Management Holding SA raised its stake in Thermo Fisher Scientific by 7.2% during the first quarter. Pictet Asset Management Holding SA now owns 2,879,274 shares of the medical research company's stock worth $1,432,816,000 after purchasing an additional 193,378 shares during the period. Institutional investors and hedge funds own 89.23% of the company's stock.

Analyst Upgrades and Downgrades

Several analysts have recently commented on TMO shares. The Goldman Sachs Group set a $610.00 price target on shares of Thermo Fisher Scientific and gave the company a "buy" rating in a research report on Wednesday, April 23rd. Barclays raised their target price on Thermo Fisher Scientific from $450.00 to $490.00 and gave the stock an "equal weight" rating in a research note on Thursday, July 24th. HSBC reiterated a "hold" rating and set a $510.00 price target on shares of Thermo Fisher Scientific in a report on Thursday, July 24th. Royal Bank Of Canada dropped their target price on shares of Thermo Fisher Scientific from $651.00 to $637.00 and set an "outperform" rating for the company in a report on Thursday, April 24th. Finally, Wall Street Zen downgraded shares of Thermo Fisher Scientific from a "buy" rating to a "hold" rating in a report on Sunday, August 10th. Sixteen analysts have rated the stock with a Buy rating and six have given a Hold rating to the company's stock. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and an average target price of $593.00.

Insider Activity

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 295 shares of Thermo Fisher Scientific stock in a transaction that occurred on Wednesday, August 20th. The stock was sold at an average price of $500.04, for a total transaction of $147,511.80. Following the transaction, the chief executive officer owned 115,174 shares of the company's stock, valued at $57,591,606.96. The trade was a 0.26% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, EVP Gianluca Pettiti sold 400 shares of Thermo Fisher Scientific stock in a transaction that occurred on Friday, July 25th. The stock was sold at an average price of $479.98, for a total value of $191,992.00. Following the transaction, the executive vice president directly owned 22,367 shares in the company, valued at approximately $10,735,712.66. This trade represents a 1.76% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 18,896 shares of company stock worth $8,593,838 in the last three months. Corporate insiders own 0.33% of the company's stock.

Thermo Fisher Scientific Stock Down 2.3%

Shares of TMO traded down $11.3820 during midday trading on Thursday, hitting $483.4280. The company had a trading volume of 1,360,628 shares, compared to its average volume of 2,488,796. The company's 50-day simple moving average is $439.69 and its 200-day simple moving average is $458.78. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.50 and a current ratio of 1.93. The firm has a market capitalization of $182.55 billion, a P/E ratio of 27.96, a P/E/G ratio of 2.66 and a beta of 0.74. Thermo Fisher Scientific Inc. has a 1 year low of $385.46 and a 1 year high of $627.88.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last announced its quarterly earnings data on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.22 by $0.14. The business had revenue of $10.86 billion during the quarter, compared to analysts' expectations of $10.68 billion. Thermo Fisher Scientific had a return on equity of 16.82% and a net margin of 15.24%.The business's quarterly revenue was up 2.9% compared to the same quarter last year. During the same quarter last year, the business posted $5.37 EPS. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. As a group, sell-side analysts expect that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current year.

Thermo Fisher Scientific Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, October 15th. Stockholders of record on Monday, September 15th will be given a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a dividend yield of 0.4%. The ex-dividend date of this dividend is Monday, September 15th. Thermo Fisher Scientific's dividend payout ratio (DPR) is 9.95%.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.